IVOSIDENIB-CHONDRO-P1

NCT02073994 📎

Regimen

Experimental
Ivosidenib 500 mg PO QD continuous (oral IDH1 inhibitor, Tibsovo)
Control
none (single-arm phase 1)

Population

Advanced unresectable/metastatic conventional chondrosarcoma with centrally confirmed IDH1 R132 mutation, progressed on prior therapy or no standard option

Key finding

First prospective evidence that a targeted therapy produces clinically meaningful disease stabilization in IDH1-mutant chondrosarcoma — a subtype historically refractory to cytotoxic chemo. Responses were not RECIST PRs but PFS and biomarker data supported a real on-target effect.

Source: PMID 32208957

Timeline

    Guideline citations

    • NCCN BONE (p.10)